AlphAIAlphAI — Financial news for AI agents
simplywall.stSEP 243 min read$ABT

How Lingo Partnership Will Impact Abbott Stock (ABT)

Abbott Laboratories (ABT) announced a partnership with Berry Street for its Lingo glucose monitor and virtual nutrition coaching. The company also reported first clinical use of its Volt PFA system in Canada and the US. Abbott projects $60.0b revenue and $9.6b earnings by 2029, with 8.8% yearly revenue growth. The partnership and Volt PFA updates support Abbott's long-term narrative, but near-term earnings risks remain due to legal and regulatory exposure in the Nutrition segment.

Original reporting
simplywall.st
Published Sep 24, 2026, 11:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
How Lingo Partnership Will Impact Abbott Stock (ABT) — source image
Source · simplywall.st
Decision brief

The 30-second read

$ABTNeutralLow
01

Why it matters

While the collaboration could broaden Abbott's addressable market, the near‑term earnings outlook remains constrained by nutrition‑related legal costs and margin pressures.

02

Market read

The news adds a modest, forward‑looking catalyst for Abbott but does not fundamentally shift its earnings outlook.

03

What to watch

Adoption rates for OTC glucose monitors and reimbursement pathways (e.g., Medicare) remain uncertain.

Relevance 6/10Novelty 5/10Timing: announced today

Background

The article provides a strategic overview of Abbott's new partnership and device usage, framing it within the company's broader growth narrative.

Company-level read

Ticker impact

$ABTNeutralMedium confidence
Context

Abbott announced an exclusive partnership with Berry Street to combine its Lingo OTC glucose monitor with virtual nutrition coaching and reported first clinical use of its Volt PFA system in Canada and the US.

Expected impact

Modest upside potential if Lingo adoption accelerates; limited short‑term move.

Evidence & confidence

New product‑service collaboration is a positive catalyst, yet the article stresses that margin rebuild and legal settlements dominate near‑term risk.

Market effects

Sector

Highlights growing convergence of medtech and digital health, potentially benefiting broader med‑device and wellness sectors.

Regional

U.S. and Canadian markets may see modest interest in Abbott and related health‑tech peers.

Global

Limited to companies with consumer health monitoring and electrophysiology devices.

Counterpoint

What could challenge this read

The partnership may be a distraction; legal settlements and high debt could outweigh incremental revenue from Lingo.

Key entities

  • company
    Abbott Laboratories

    U.S. medical device and diagnostics maker (ticker ABT).

  • company
    Berry Street

    Partner providing virtual nutrition coaching.

Read at source← All news

Related articles

SEP 21
$ABTMedAI 8/10

NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage

North Carolina settled with Abbott Laboratories for $384M over contaminated baby formula, part of a broader agreement with 39 states and the federal government. Abbott, which produces over 40% of U.S. formula, was accused of selling unsafe products and concealing test results. The recall caused a 2022 shortage. North Carolina's share is $216K, earmarked for Medicaid and nutrition programs.

wral.com2 min
SEP 21
$ABTHighAI 8/10

Abbott Laboratories To Pay $385M Over Allegations Of Tainted Infant Formula

Abbott Laboratories will pay $385M to resolve allegations of tainted infant formula. The settlement includes $348.7M to the federal government and $35.5M to state Medicaid programs. California's share is over $15M. The allegations span 2018-2022, involving production conditions that risked microorganism contamination. Abbott recalled several formula brands in 2022, leading to a nationwide shortage.

patch.com2 min
SEP 20
$ABTLowAI 8/10

Sunday Edition: Sodium

Abbott Laboratories agreed to pay $384.9M to settle a DOJ case over a 2022 infant formula outbreak. The settlement doesn't determine liability. Pending lawsuits remain. No specific company was named in an E. coli and Salmonella outbreak linked to seed supplier Everything Sprouts LLC. Italy's hepatitis A outbreak affected 130 people, possibly from bivalve mollusks. UK small businesses show good food safety practices but low awareness of food crime.

foodsafetynews.com4 min
SEP 20
$ABTLow

State settles infant formula contamination lawsuit, more Health Headlines

Colorado will receive nearly $2 million from Abbott Laboratories as part of a $348 million settlement over allegations of misrepresenting the safety of its infant formula, with additional $35.5 million to be split among states. The lawsuit claimed Abbott failed to maintain safety standards and disclose contamination test results. The funds will be returned to Colorado's Medicaid program.

gjsentinel.com2 min
SEP 19
$ABTMedAI 8/10

Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.

wpdh.com2 min